Surveillance for Guillain-Barré syndrome after 2015–2016 and 2016–2017 influenza vaccination of Medicare beneficiaries-Reference-Cited by-同舟云学术

Surveillance for Guillain-Barré syndrome after 2015–2016 and 2016–2017 influenza vaccination of Medicare beneficiaries

Published:2019-10 Issue:43 Volume:37 Page:6543-6549
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Arya Deepa P.,Said Maria A.,Izurieta Hector S.,Perez-Vilar Silvia,Zinderman Craig,Wernecke Michael,Alexander Michael,White Taylor,Su I-Hsuan,Lufkin Bradley,MaCurdy Thomas,Kelman Jeffrey,Forshee Richard

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference37 articles.

1. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977;Schonberger;Am J Epidemiol,1979

2. Evaluation of Guillain-Barre Syndrome among recipients of influenza vaccine in 2000 and 2001;Burwen;Am J Prev Med,2010

3. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines;Lasky;N Engl J Med,1998

4. Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009–2010;Polakowski;Am J Epidemiol,2013

5. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis;Salmon;Lancet,2013

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine patterns among older adults with Guillain–Barré syndrome and matched comparators, 2006–2019;Journal of the American Geriatrics Society;2024-08

2. Evaluating algorithms for identifying incident Guillain-Barré Syndrome in Medicare fee-for-service claims;Global Epidemiology;2024-06

3. Assessment of potential adverse events following the 2022–2023 seasonal influenza vaccines among U.S. adults aged 65 years and older;Vaccine;2024-05

4. Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States;2024-01-26

5. Assessment of Potential Adverse Events Following the 2022–2023 Seasonal Influenza Vaccines Among U.S. Adults Aged 65 Years and Older;2023-09-23